Immunosuppressor XXXX increases @entity6459 and activin receptor-like kinase 1 expression and modulates @entity2533 signaling in endothelial cells.

@entity1 @entity6459 @entity2758 @entity8721 @entity417 @entity1415 @entity344 @entity1884 @entity1578 @entity14077 @entity2533 @entity74 @entity1140 @entity99 @entity360
@entity1884 ( @entity1884 ), or @entity1884 , is an @entity74 . The clinical manifestations are @entity1415 , @entity344 , and @entity2758 in internal organs. @entity1 show severe @entity1415 , and/or @entity360 , both of which notably interfere with their quality of life. There are two predominant types of @entity1884 caused by mutations in @entity6459 ( @entity6459 ) and @entity14077 ( @entity14077 ) genes, named @entity6459 and @entity14077 , respectively. @entity6459 and @entity14077 code for proteins involved in the transforming growth factor (TGF)-b1 signaling pathway, and it is widely accepted that @entity1884 pathogenicity results from haploinsufficiency. No cure for @entity1884 has been found, so identification of drugs able to increase the expression of these genes is essential when proposing new therapies. We report the efficacy of @entity1140 ( @entity1140 ) in increasing @entity6459 and @entity14077 expression. The rationale comes from a case report of a @entity1 with @entity1884 who received a liver transplantation after @entity1578 due to a @entity99 . The liver was transplanted, and the immunosuppressor @entity1140 was used to prevent the rejection. After the first month of @entity1140 treatment, the internal and external @entity8721 , epistaxes, and @entity417 disappeared. Here, we find that the immunosuppressor @entity1140 increases the protein and mRNA expression of @entity6459 and @entity14077 in cultured endothelial cells and enhances the @entity2533 / @entity14077 signaling pathway and endothelial cell functions like tubulogenesis and migration. These results suggest that the mechanism of action of @entity1140 involves a partial correction of @entity6459 and @entity14077 haploinsufficiency and may therefore be an interesting drug for use in @entity1 with @entity1884 who undergo transplantation.
